ABSTRACT
During a 15-year-period 62 adult patients were admitted with diagnosis of Schoenlein-Henoch purpura in our hospital. 25 female and 37 male patients ranged from 30-87 years (mean: 59.5 years) presenting with cutaneous, joint, renal and particularly abdominal involvement were investigated retrospectively. During the course of the disease, all patients developed purpuric rash (100 %), 14 (22,5 %) patients had joint symptoms and renal involvement occurred in 12 (19,3 %) patients. In this study, we discuss 15 (24 %) patients with gastrointestinal symptoms appearing in Henoch's purpura. Analysis of the gastrointestinal clinical features revealed: Abdominal pain 13 (86 %), massive colorectal bleeding 3 (20 %), occult blood loss 10 (66 %) vomiting 6 (40 %) and diarrhea in 3 (20 %) patients. Surgical consultation was obtained for 4 of the 15 patients and laparotomy was performed in 2 patients. All the patients underwent lower and upper endoscopic examination, in 3 cases the authors saw purpuric mucosal lesions in duodenum and in 8 patients were also found coin-like elevated lesions, additionally, biopsy from colonic lesions showed leukocytoclastic vasculitis. It is concluded that endoscopy may play a very important role in the diagnosis and treatment of Schoenlein-Henoch purpura.
Subject(s)
Endoscopy, Gastrointestinal , Gastrointestinal Diseases/diagnosis , IgA Vasculitis/diagnosis , Adult , Aged , Aged, 80 and over , Biopsy , Diagnosis, Differential , Female , Gastrointestinal Diseases/pathology , Gastrointestinal Diseases/surgery , Gastrointestinal Hemorrhage/etiology , Humans , IgA Vasculitis/pathology , IgA Vasculitis/surgery , Intestinal Mucosa/pathology , Male , Middle AgedABSTRACT
In this work, the effect of eradication of Helicobacter pylori on complaints and symptoms of infected, primary Raynaud's syndrome patients was studied. Altogether 92 Helicobacter pylori positive patients with gastric complaints and with primary Raynaud's syndrome received eradication therapy. In this prospective study, before and after the eradication the severity and frequency of the complaints and symptoms of the patients were recorded. The eradication was performable in 89 patients; in 75 cases the eradication was successful. In the eradicated patients frequency and duration of Raynaud attacks were improved related to those of the not eradicated group. These results might suggest a potential etiopathogenetical role of Helicobacter pylori infection in the pathogenesis of the primary Raynaud's syndrome.
Subject(s)
Helicobacter Infections/drug therapy , Helicobacter pylori , Raynaud Disease/diagnosis , Raynaud Disease/microbiology , Acute Disease , Adult , Female , Helicobacter Infections/complications , Helicobacter pylori/drug effects , Humans , Prospective Studies , Severity of Illness IndexABSTRACT
The authors have been working on the cytostatic treatment of gastric cancer since 1982. The patients were divided into two groups. Group 1.: Patients who had been operated radically on gastric cancer. Group 2.: Patients who had advanced gastric cancer. The following cytostatic drugs were administrated: Cyclophosphamide, Vincristine, Ftorafur. The patients who had been operated on radically were given adjuvant cytostatic treatment for 3 months according to their own protocol. The patients advanced gastric cancer got life long systemic cytostatic treatment. Between 1982 and 1989, 36 histologically proven gastric carcinoma patients were treated. The effectiveness of the therapy was measured by the survival time from the beginning of the cytostatic treatment. The control group 67 patients consisted of radically or palliative operated patients of the surgical department of those who had not got chemotherapeutic treatment. According to the experiences of the authors, the survival time was prolonged considerably by cytostatic treatment in the group of palliative operated or inoperable patients.
